Company Monitoring Page for Eisai

latest headlines for company on cafepharma

Eisai and Biogen facing delay to Leqembi in Europe
Pharmaphorum
Mon, 03/25/24 - 11:22 am
Tags:
Eisai, Biogen, Leqembi, Europe, Alzheimer's disease
Eisai backs Leqembi’s Japan rollout with insurance policy
Pharmaphorum
Thu, 03/21/24 - 11:19 am
Tags:
Eisai, Lifenet, insurance, Leqembi, dementia
FDA guidelines consider amyloid reduction 'reasonably likely' to predict Alzheimer's benefit
Fierce Biotech
Tue, 03/12/24 - 11:34 am
Tags:
Biogen, Eisai, Aduhelm, FDA, Alzheimer's disease, amyloid, Eli Lilly, donanemab
Tau, anti-inflammation and orals form Biogen's future Alzheimer's pipeline
Fierce Biotech
Thu, 03/7/24 - 11:38 am
Tags:
Biogen, Alzheimer's disease, anti-tau antibodies, anti-inflammatory, Eisai, Leqembi
Japan's Eisai says US introduction of Alzheimer's drug Leqembi slower than expected
Reuters
Thu, 03/7/24 - 11:07 am
Tags:
Eisai, Leqembi, drug launches, Alzheimer's disease
Eisai, Biogen likely to miss early launch goal for Alzheimer's drug Leqembi
Fierce Pharma
Wed, 02/7/24 - 11:33 am
Tags:
Eisai, Biogen, FDA, Medicare, Leqembi, Alzheimer's disease
EU regulators to consult advisers in review of Eisai Alzheimer’s drug
BioPharma Dive
Thu, 01/11/24 - 08:40 pm
Tags:
Eisai, Leqembi, Europe, Alzheimer's disease
Eisai files biliary tract cancer drug tasurgratinib in Japan
Pharmaphorum
Mon, 12/18/23 - 10:14 am
Tags:
Eisai, Japan, tasurgratinib, biliary tract cancer
Merck-Eisai's endometrial cancer therapy combo fails first-line treatment trial
Reuters
Fri, 12/8/23 - 09:59 am
Tags:
Merck, Eisai, 4523.T, clinical trials, endometrial cancer, Keytruda, Lenvima
Eisai expects Alzheimer's drug to rake in revenue of $66.5 million by March
Reuters
Tue, 11/7/23 - 09:57 am
Tags:
Eisai, Leqembi, Alzheimer's disease
Eisai says new data could support more convenient form of Alzheimer’s drug Leqembi
BioPharma Dive
Wed, 10/25/23 - 10:42 pm
Tags:
Eisai, Biogen, Leqembi, Alzheimer's disease
As 'harvest time' arrives for Alzheimer's, neuroscientist reflects on next steps for drug development
Fierce Biotech
Mon, 10/16/23 - 10:12 am
Tags:
Alzheimer's disease, Biogen, Eisai, Eli Lilly, Leqembi, donanemab
Biogen's Aduhelm headache returns as appeals court revives part of investor lawsuit
Fierce Pharma
Thu, 10/12/23 - 05:18 pm
Tags:
Biogen, Aduhelm, legal, Eisai, Alzheimer's disease
6 Drugs Approved Despite Failed Trials or Minimal Data
BioSpace
Mon, 10/9/23 - 11:10 am
Tags:
Ipsen, Sohonos, Sarepta Therapeutics, Elevidys, Biogen, Qalsody, Eisai, Aduhelm, Jazz Pharma, PharmaMar, Zepzelca, Acadia Pharma, Nuplazid
Japan approves Alzheimer's treatment Leqembi by Eisai and Biogen
Reuters
Tue, 09/26/23 - 10:23 am
Tags:
Biogen, Eisai, Japan, Leqembi, Alzheimer's disease
Merck and Eisai's Keytruda-Lenvima combo chalks up 2 more losses, this time in non-small cell lung cancer
Fierce Pharma
Fri, 09/22/23 - 11:46 am
Tags:
Merck, Eisai, Keytruda, Lenvima, melanoma, colorectal cancer, non-small cell lung cancer
Eisai launches digital dementia specialist company
Pharmaphorum
Tue, 09/12/23 - 12:06 pm
Tags:
Eisai, digital health, dementia, Theoria Technologies
The Alzheimer’s Treatment Landscape: Leqembi vs. Donanemab
BioSpace
Mon, 09/11/23 - 11:56 am
Tags:
Alzheimer's disease, Eli Lilly, Biogen, Eisai, Leqembi, donanemab
Merck, Eisai Drop Phase III Keytruda-Lenvima Trial for Head and Neck Cancer
BioSpace
Sun, 08/27/23 - 04:40 pm
Tags:
Merck, Eisai, Keytruda, Lenvima, clinical trials, head and neck cancer
New Alzheimer’s drug raises hopes — along with questions
Medical Marketing and Media
Mon, 08/14/23 - 06:54 pm
Tags:
FDA, Alzheimer's disease, Eisai, Biogen, Leqembi

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.